eDruginfo.com - antihemophilic factor (recombinant)

Drug Updates | New Drugs

   Drug Updates
       New Drugs
       New Indications
   Patient Teaching

News Capsules

Drug Warnings

Herbal Spotlight

Quik Tools

Drug Info Links

Drug Info Bookstore

Feedback

Registration

Disclaimer

antihemophilic factor (recombinant)
Xyntha	Pharmaceutical company: Wyeth www.wyeth.com

Pharmacologic classification: coagulation factor
Therapeutic classification: hemostasis
Pregnancy risk category: C

AVAILABLE FORMS
Single-use vials: 250, 500, 1,000, 2,000 International Units

INDICATIONS AND DOSAGES
Control and prevention of bleeding episodes in patients with hemophilia A; surgical prophylaxis in patients with hemophilia A--
Adults: I.V. injection dosage (body wt [kg] x desired factor VIII rise [International Unit/dl] x 0.5 [International Unit/kg per International Unit/dl]; repeated every 8 to 24 hours as necessary, depending on bleeding severity.

CONTRAINDICATIONS AND CAUTIONS
Contraindicated in patients hypersensitive to hamster proteins.
Use cautiously in patients receiving other antihemophilic products.
Use cautiously in pregnant or breast-feeding patients.

INTERACTIONS
None reported.

ADVERSE REACTIONS
CNS: headache, asthenia, pyrexia.
GI: nausea, vomiting, diarrhea.
Other: neutralizing antibody formation.

Reactions may be common, uncommon, life-threatening, or COMMON AND LIFE-THREATENING.

Home - Guest Registry - Customer Service